This Week, We’re Talking About Atrial Fibrillation (AFib) 💓 #HeartMonth Atrial fibrillation (AFib) is the most common heart rhythm disorder, affecting over 5 million Americans today, with that number expected to rise to more than 12 million by 2030 (American Heart Association). In Canada, an estimated 200,000 people are living with AFib, and the prevalence increases with age. AFib occurs when the heart’s upper chambers (atria) beat irregularly and out of sync with the lower chambers. This disrupts normal blood flow and significantly increases the risk of stroke, heart failure, and other complications. In fact, AFib is associated with a fivefold increased risk of stroke and doubles the risk of heart-related deaths (National Institutes of Health). 🔍 What Causes Atrial Fibrillation? Several factors can contribute to the development of AFib, including: ✔️ High blood pressure – Can strain and enlarge the heart ✔️ Coronary artery disease – Narrowed arteries reduce blood flow to the heart ✔️ Heart failure – Weakens the heart muscle over time ✔️ Heart valve disease – Can alter blood flow and increase risk ✔️ Sleep apnea – Interruptions in breathing can trigger AFib ✔️ Obesity & diabetes – Increase inflammation and heart strain ✔️ Excessive alcohol or stimulant use – Can disrupt normal heart rhythms ✔️ Aging – The likelihood of AFib increases as we get older ⚠️ Common Symptoms of AFib: AFib symptoms can range from mild to severe—or may not appear at all. These can include: ✔️ Fatigue ✔️ Shortness of breath ✔️ Dizziness or lightheadedness ✔️ Heart palpitations (rapid, fluttering, or pounding heartbeat) ✔️ Chest pain or discomfort ✔️ No symptoms (silent AFib) Because AFib may go unnoticed, many people are diagnosed only after a stroke or serious complication occurs. Early detection and treatment are critical to reducing risks. 💡 Types of Atrial Fibrillation: AFib can be classified into different categories based on duration and recurrence: 🔹 Paroxysmal AFib – Occurs occasionally and may resolve on its own 🔹 Persistent AFib – Lasts more than 7 days and may require treatment 🔹 Long-standing Persistent AFib – Lasts longer than 12 months 🔹 Permanent AFib – Ongoing AFib that is resistant to treatments At Thryv Therapeutics, we’re committed to developing innovative therapies to help those affected by atrial fibrillation and other cardiovascular diseases. Our research focuses on SGK1 inhibitors, a novel approach targeting underlying disease mechanisms to improve outcomes and reduce risks. Stay tuned as we continue the conversation on heart health this Heart Month! ❤️ #AtrialFibrillation #AFibAwareness #HeartHealth #StrokePrevention #ThryvTherapeutics #HeartMonth #SGK1
